Why Wall Street Is Watching This Week's FDA Peptide Compounding Vote
TL;DR: Fortune (20 Jul 2026): telehealth firms like Hims are eyeing a ~$30bn peptide market ahead of the FDA's 23-24 Jul PCAC vote.
What Did Fortune Report About the FDA's Peptide Vote?
With the 23–24 July PCAC hearing now just days away, coverage of the vote has shifted from regulatory trade press to business and markets reporting. On 20 July 2026, Fortune published a piece arguing the FDA's Pharmacy Compounding Advisory Committee vote could create “telehealth's next multibillion-dollar market,” framing the hearing as a potential inflection point for companies that already built compounding-based businesses around semaglutide and tirzepatide.[1]
The article reports that Hims & Hers chief medical officer Dr Anant Vinjamoori is scheduled to testify at the hearing on Thursday 23 July, and that telehealth platforms including Ro and Solace are watching the outcome closely. The seven peptides under review — BPC-157, TB-500, KPV and MOTS-c on day one, DSIP (emideltide), Semax and Epitalon on day two — are all compounds that came off the FDA's Category 2 “may not be compounded” list in April 2026, which is what teed up this review in the first place.
How Big Is the Addressable Peptide Market, According to Analysts?
Fortune's reporting cites Needham research sizing the combined addressable peptide market — existing grey-market use, GLP-1 “add-on” peptides sold alongside semaglutide or tirzepatide prescriptions, and general health-optimisation peptides — at roughly $30 billion. That figure is a market-opportunity estimate from an equity-research note, not a regulatory or clinical finding, and it has not been independently verified by Velox Peptides.
The article also quotes Wheel Health CEO Michelle Davey, who predicts that large telehealth players will move quickly once a legal compounding pathway opens, comparing the likely rush to the more than 80 Shopify-based GLP-1 clinics that launched by late 2024 once semaglutide and tirzepatide compounding became a viable business line. Her forecast is that a positive PCAC outcome would trigger a similar wave of copycat “peptide programs” across the telehealth sector.[1]
Are Investors Already Pricing This In?
Some of that positioning shows up in analyst notes published ahead of the hearing. On 1 July 2026, Canaccord Genuity analyst Maria Ripps raised her price target on Hims & Hers stock from $32 to $40 while maintaining a Buy rating, citing continued momentum in the company's weight-loss business alongside “growing enthusiasm” around its peptide opportunity, according to Investing.com's coverage of the note.[2]
Read this as market commentary, not a regulatory signal. An analyst price target reflects one firm's view of a stock's likely trading range — it is not a prediction of how the PCAC will vote, and it has no bearing on whether any of the seven peptides under review will actually be added to the 503A Bulk Drug Substances list.
Would a Positive PCAC Vote Make These Peptides Available Immediately?
No. As covered in our earlier reporting on the docket, the PCAC's recommendation is advisory only. The FDA separately reviews it and decides whether to begin formal rulemaking to add any of the seven peptides to the Section 503A Bulk Drug Substances Category 1 list. Even a unanimous committee vote to approve would not create an overnight legal compounding pathway for telehealth platforms to prescribe against — that requires a subsequent FDA rulemaking process with its own timeline, which is a materially slower and more uncertain step than Fortune's “multibillion-dollar market” framing might suggest.
It is also worth separating this 503A compounding-pharmacy pathway from full drug approval entirely. A compounded peptide dispensed under 503A is prepared by a licensed pharmacy against an individual prescription for an unapproved substance; it is not the same as an FDA-approved medicine with its own New Drug Application. Retatrutide, for example, follows a completely separate regulatory track — Eli Lilly's own NDA filing is targeted for Q4 2026, with FDA review and any approval decision handled independently of anything the PCAC votes on this week.
| Step | Status this week |
|---|---|
| PCAC hearing & vote | 23–24 July 2026 — advisory recommendation only |
| FDA rulemaking decision | Follows separately; no fixed timeline published |
| 503A compounding pathway live | Not yet — requires completed rulemaking |
| Full FDA drug approval (e.g. retatrutide NDA) | Entirely separate process — not decided by PCAC |
What Does a US Telehealth Peptide Market Mean for UK Researchers?
Nothing changes on this side of the Atlantic. The 503A Bulk Drug Substances List, the PCAC advisory process, and the prescription-telehealth business model Fortune describes are all US-specific mechanisms governed by US federal law and FDA guidance. None of it alters the regulatory status of research peptides in the UK, which sits under the Human Medicines Regulations 2012 and MHRA guidance — see our guide on whether research peptides are legal in the UK.
It is also a different business model in kind, not just jurisdiction. A US telehealth platform compounding under a 503A pathway would be dispensing a prepared product against an individual patient prescription. Velox Peptides supplies BPC-157, TB-500, KPV, MOTS-c, Semax and DSIP as HPLC-verified in vitro research reagents only — there is no prescription, no human dosing guidance, and no health claim attached to any product we sell, regardless of how the US market for these compounds develops.
These compounds are supplied as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Fortune. The FDA's peptide vote could create telehealth's next multibillion-dollar market. 20 July 2026. fortune.com
- Investing.com. Canaccord raises Hims and Hers stock price target on weight loss drugs. 1 July 2026. investing.com
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Docket FDA-2025-N-6895. fda.gov
Frequently Asked Questions
What did Fortune report about the FDA's peptide vote and telehealth?
On 20 July 2026, Fortune reported that telehealth companies including Hims & Hers, Ro and Solace are positioning to enter the peptide-compounding market ahead of the FDA's Pharmacy Compounding Advisory Committee (PCAC) vote on 23-24 July 2026. Hims chief medical officer Dr Anant Vinjamoori is scheduled to testify at the hearing, and the article cites Needham research sizing the addressable peptide market at roughly $30 billion.
Which peptides does the 23-24 July 2026 PCAC vote cover?
The committee reviews seven peptides for the Section 503A Bulk Drug Substances Category 1 list: BPC-157, TB-500, KPV and MOTS-c on 23 July, and DSIP (emideltide), Semax and Epitalon on 24 July. All seven were removed from the FDA's Category 2 "may not be compounded" list on 23 April 2026, which is what enabled this review.
Would a positive PCAC vote make these peptides available on telehealth platforms immediately?
No. The PCAC's recommendation is advisory only. The FDA separately reviews it and decides whether to begin formal rulemaking to add any of the seven peptides to the 503A Bulk Drug Substances list. Even a unanimous recommendation to approve would not create an immediate legal compounding pathway - that requires a subsequent FDA rulemaking process with its own timeline, distinct from a full New Drug Application approval.
Why are telehealth stocks reacting to a pharmacy-compounding committee vote?
On 1 July 2026, Canaccord Genuity analyst Maria Ripps raised her price target on Hims & Hers from $32 to $40 while maintaining a Buy rating, citing weight-loss momentum and growing enthusiasm around the company's peptide opportunity, according to Investing.com. Telehealth platforms already built compounding-based businesses around semaglutide and tirzepatide; a favourable 503A pathway for BPC-157, TB-500 and the other five peptides would let them extend that model.
Does this US telehealth story affect UK research-reagent supply?
No. The 503A Bulk Drug Substances List, the PCAC advisory process and US telehealth prescribing are all US-specific mechanisms governed by US federal law. None of it changes the regulatory status of research peptides in the UK, which is governed separately by the Human Medicines Regulations 2012 and MHRA guidance. Velox Peptides supplies BPC-157, TB-500, KPV, MOTS-c, Semax and DSIP strictly as HPLC-verified in vitro research reagents, not as prescription products.